<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE patent-application-publication SYSTEM "pap-v16-2002-01-01.dtd" [
<!ENTITY US20030003139A1-20030102-C00001.CDX SYSTEM "US20030003139A1-20030102-C00001.CDX" NDATA CDX>
<!ENTITY US20030003139A1-20030102-C00001.MOL SYSTEM "US20030003139A1-20030102-C00001.MOL" NDATA MOL>
<!ENTITY US20030003139A1-20030102-C00001.TIF SYSTEM "US20030003139A1-20030102-C00001.TIF" NDATA TIF>
<!ENTITY US20030003139A1-20030102-D00001.TIF SYSTEM "US20030003139A1-20030102-D00001.TIF" NDATA TIF>
]>
<patent-application-publication>
<subdoc-bibliographic-information>
<document-id>
<doc-number>20030003139</doc-number>
<kind-code>A1</kind-code>
<document-date>20030102</document-date>
</document-id>
<publication-filing-type>new</publication-filing-type>
<domestic-filing-data>
<application-number>
<doc-number>10022834</doc-number>
</application-number>
<application-number-series-code>10</application-number-series-code>
<filing-date>20011220</filing-date>
</domestic-filing-data>
<foreign-priority-data>
<priority-application-number>
<doc-number>00250449.6</doc-number>
</priority-application-number>
<filing-date>20001221</filing-date>
<country-code>EP</country-code>
</foreign-priority-data>
<technical-information>
<classification-ipc>
<classification-ipc-primary>
<ipc>A61K031/57</ipc>
</classification-ipc-primary>
<classification-ipc-secondary>
<ipc>A61K009/70</ipc>
</classification-ipc-secondary>
<classification-ipc-edition>07</classification-ipc-edition>
</classification-ipc>
<classification-us>
<classification-us-primary>
<uspc>
<class>424</class>
<subclass>449000</subclass>
</uspc>
</classification-us-primary>
<classification-us-secondary>
<uspc>
<class>514</class>
<subclass>178000</subclass>
</uspc>
</classification-us-secondary>
</classification-us>
<title-of-invention>Transdermal system that contains a new highly potent gestagen</title-of-invention>
</technical-information>
<inventors>
<first-named-inventor>
<name>
<given-name>Ralph</given-name>
<family-name>Lipp</family-name>
</name>
<residence>
<residence-non-us>
<city>Berlin</city>
<country-code>DE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</first-named-inventor>
<inventor>
<name>
<given-name>Clemens</given-name>
<family-name>Gunther</family-name>
</name>
<residence>
<residence-non-us>
<city>Berlin</city>
<country-code>DE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
</inventors>
<assignee>
<organization-name>Schering AG</organization-name>
<address>
<city>Berlin</city>
<postalcode>D-13353</postalcode>
<country>
<country-code>DE</country-code>
</country>
</address>
<assignee-type>03</assignee-type>
</assignee>
<correspondence-address>
<name-1>MILLEN, WHITE, ZELANO &amp; BRANIGAN, P.C.</name-1>
<name-2></name-2>
<address>
<address-1>2200 CLARENDON BLVD.</address-1>
<address-2>SUITE 1400</address-2>
<city>ARLINGTON</city>
<state>VA</state>
<postalcode>22201</postalcode>
<country>
<country-code>US</country-code>
</country>
</address>
</correspondence-address>
</subdoc-bibliographic-information>
<subdoc-abstract>
<paragraph id="A-0001" lvl="0">Matrix-transdermal system that contains (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione that comprises a polyacrylate adhesive. </paragraph>
</subdoc-abstract>
<subdoc-description>
<summary-of-invention>
<paragraph id="P-0001" lvl="0"><number>&lsqb;0001&rsqb;</number> The invention relates to a transdermal system (TDS) of highly potent gestagen(s), especially of (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione, referred to below as hydroxytrienedione (<cross-reference target="DRAWINGS">FIG. 1</cross-reference>).  
<chemistry-cwu id="CHEM-US-00001">
<number>1</number>
<image id="EMI-C00001" he="86.184" wi="140.64435" file="US20030003139A1-20030102-C00001.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00001" file="US20030003139A1-20030102-C00001.CDX"/>
<chemistry-mol-file id="CHEMMOL-00001" file="US20030003139A1-20030102-C00001.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0002" lvl="7"><number>&lsqb;0002&rsqb;</number> <cross-reference target="DRAWINGS">FIG. 1</cross-reference>: Structural formula of hydroxytrienedione </paragraph>
<paragraph id="P-0003" lvl="0"><number>&lsqb;0003&rsqb;</number> Transdermal systems are a special form of transdermal formulations. </paragraph>
<paragraph id="P-0004" lvl="0"><number>&lsqb;0004&rsqb;</number> For the purpose of the application, the term &ldquo;transdermal system&rdquo; is used in a narrow definition for all transdermal patch formulations. Usually, transdermal systems are subdivided into matrix-transdermal systems and membrane-transdermal systems. </paragraph>
<paragraph id="P-0005" lvl="0"><number>&lsqb;0005&rsqb;</number> In the simplest case, matrix-transdermal systems consist of three layers that are arranged parallel over one another, namely a back layer, a matrix and a peel-off layer. The latter, which usually consists of plastic film or coated paper, is removed before the transdermal system is applied to the skin. The matrix contains the active ingredient that is to be administered and usually simultaneously has adhesive properties. Should the matrix not be adhesive enough to adhere reliably to the skin area on which the transdermal system is to be administered, an adhesive layer can still be provided between matrix and peel-off layer. </paragraph>
<paragraph id="P-0006" lvl="0"><number>&lsqb;0006&rsqb;</number> In the simplest case, membrane-transdermal systems consist of four layers, namely a back layer, a reservoir, a membrane and a peel-off layer. The reservoir, which can contain active ingredients and adjuvants, is usually completely surrounded by back layer and membrane. The components of the reservoir can be released through the membrane. Since a number of membranes are not sufficiently adhesive to adhere to the skin area on which the transdermal system is to be administered, an adhesive layer is generally provided between membrane and peel-off layer (at least in the edge area). It is known that gestagens can be administered transdermally. The gestagens previously used in formulations for transdermal systems generally have relatively low solubilities in the matrices used, however, e.g., gestodene or levonorgestrel about 1%. A crystal-free transdermal system can be produced with these gestagens only if the content of gestagen in the matrix does not significantly exceed the saturation concentration. </paragraph>
<paragraph id="P-0007" lvl="0"><number>&lsqb;0007&rsqb;</number> A high content of gestagen in the matrix is often desired to achieve sufficient transdermal skin flows. </paragraph>
<paragraph id="P-0008" lvl="0"><number>&lsqb;0008&rsqb;</number> Other gestagens have a higher solubility, such as, e.g., norethistosterone (about 7%), but their gestagenic potency is comparatively low. </paragraph>
<paragraph id="P-0009" lvl="0"><number>&lsqb;0009&rsqb;</number> The object of the invention is therefore to make available a transdermal system with a high content of highly potent gestagens in dissolved form. </paragraph>
<paragraph id="P-0010" lvl="0"><number>&lsqb;0010&rsqb;</number> According to the invention, this object is achieved by a transdermal system with a content of the highly potent gestagen (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione (hydroxytrienedione). </paragraph>
<paragraph id="P-0011" lvl="0"><number>&lsqb;0011&rsqb;</number> In an embodiment, the invention provides that (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione is present in a matrix, especially an adhesive matrix. </paragraph>
<paragraph id="P-0012" lvl="0"><number>&lsqb;0012&rsqb;</number> As medically acceptable adhesives, for example, polyacrylate, silicone or polyisobutylene adhesives can be used. Moreover, polyurethanes, block-copolymers based on styrene and other organic polymers can be used, however. </paragraph>
<paragraph id="P-0013" lvl="0"><number>&lsqb;0013&rsqb;</number> Polyacrylate adhesives are preferred. </paragraph>
<paragraph id="P-0014" lvl="0"><number>&lsqb;0014&rsqb;</number> For the purpose of the patent, polyacrylate is the generic term for all polymers (homopolymers and copolymers) that contain acrylic acid or acrylic acid derivatives. Especially preferred are vinyl acetate-acrylate-copolymers and acrylate-vinylpyrrolidone-copolymers, and most preferred are 2-ethylhexylacrylate-hydroxyethylacrylate-copolymers (Gelva<highlight><superscript>(R)</superscript></highlight>) as well as copolymers of the above-mentioned compounds with other substances, such as, for example, vinyl acetate and 2-ethylhexylacrylate-N-vinyl-2-pyrrolidone (TSR<highlight><superscript>(R)</superscript></highlight>-adhesive of the Sekisui Company). </paragraph>
<paragraph id="P-0015" lvl="0"><number>&lsqb;0015&rsqb;</number> A content of 0.1 to 20% by weight of hydroxytrienedione ((21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione), preferably 1 to 15% by weight, is provided in the matrix. </paragraph>
<paragraph id="P-0016" lvl="0"><number>&lsqb;0016&rsqb;</number> In an especially preferred embodiment, the transdermal formulation according to the invention contains crystallization inhibitors that are suitable as complexing agents to form, for example, solid solutions with active ingredient that increase the interfacial solubility for the active ingredient and reduce the tendency of the active ingredient to recrystallization after a process solvent is removed or the temperature is dropped. The addition of crystallization inhibitors makes it possible to undertake higher active ingredient loadings of the formulation without active ingredient crystals forming, which are available to an only very limited extent for mass transfer into the skin. As crystallization inhibitors, N-vinyllactam polymers, such as N-vinyl-1-aza-cycloheptan-2-one-homopolymers and N-vinyl-piperidin-2-one-homopolymers and especially polymers of vinylpyrrolidone, such as polyvidone (Kollidon<highlight><superscript>(R)</superscript></highlight>) or co-polymers of vinylpyrrolidone with vinyl acetate (copovidones) are suitable. Especially preferred is a copovidone that consists of 6 parts vinylpyrrolidone and 4 parts vinyl acetate (Kollidon<highlight><superscript>(R) </superscript></highlight>VA 64). </paragraph>
<paragraph id="P-0017" lvl="0"><number>&lsqb;0017&rsqb;</number> The content of crystallization inhibitor in the transdermal system according to the invention is 0.1 to 40%, preferably 2 to 20%. </paragraph>
<paragraph id="P-0018" lvl="0"><number>&lsqb;0018&rsqb;</number> The system according to the invention preferably has an additional content of at least one penetration intensifier. </paragraph>
<paragraph id="P-0019" lvl="0"><number>&lsqb;0019&rsqb;</number> As penetration intensifiers, the following can be used: </paragraph>
<paragraph id="P-0020" lvl="0"><number>&lsqb;0020&rsqb;</number> Monovalent or multivalent alcohols such as ethanol, 1,2-propanediol or benzyl alcohol; saturated or unsaturated fatty alcohols with 8 to 18 carbon atoms, such as lauryl alcohol or cetyl alcohol; hydrocarbons such as mineral oil; saturated and unsaturated fatty acids with 8 to 18 carbon atoms such as stearic acid or oleic acid; fatty acid esters with up to 24 carbon atoms or dicarboxylic acid diesters with up to 24 carbon atoms, such as methyl ester, ethyl ester, isopropyl ester, butyl ester, sec-butyl ester, isobutyl ester, tert-butyl ester or monoglyceric acid ester of acetic acid, caproic acid, lauric acid, myristic acid, stearic acid and palmitic acid, phosphatide derivatives, such as lecithin, terpenes, urea and its derivatives or ethers, such as dimethyl isosorbide and diethylene glycol monoethyl ether. </paragraph>
<paragraph id="P-0021" lvl="0"><number>&lsqb;0021&rsqb;</number> Especially preferred are lauryl alcohol, 1,2-propanediol, methyl ester and especially the isopropyl ester of myristic acid or oleic acid, diisopropyl adipate and diisopropyl sebacate, lauric acid and oleic acid, as well as mixtures thereof. </paragraph>
<paragraph id="P-0022" lvl="0"><number>&lsqb;0022&rsqb;</number> In addition, mixtures that consist of one or more penetration-intensifying agents can also be used for the transdermally active formulation according to the invention. Here, mixtures of up to four penetration intensifiers are used. The use of binary and ternary penetration intensifier mixtures is preferred. Most preferred is the use of binary penetration intensifier mixtures that consist of hydrophilic with lipophilic penetration intensifiers. </paragraph>
<paragraph id="P-0023" lvl="0"><number>&lsqb;0023&rsqb;</number> Examples are enhancer mixtures of fatty acid esters or fatty acids with short-chain, monovalent or divalent alcohols in a ratio of 1:10 to 10:1. A preferred mixture ratio is 3:1 to 1:3. </paragraph>
<paragraph id="P-0024" lvl="0"><number>&lsqb;0024&rsqb;</number> The content of penetration intensifiers or penetration intensifier mixtures in the transdermal system according to the invention is 0.5 to 40%, preferably 5 to 25%. </paragraph>
<paragraph id="P-0025" lvl="0"><number>&lsqb;0025&rsqb;</number> Moreover, stabilizers such as cyclodextrins, preferably &bgr;-cyclodextrin and derivatives thereof, can also be added to the matrix. </paragraph>
<paragraph id="P-0026" lvl="0"><number>&lsqb;0026&rsqb;</number> In addition, the invention is preferably characterized by an additional content of at least one estrogen. </paragraph>
<paragraph id="P-0027" lvl="0"><number>&lsqb;0027&rsqb;</number> As estrogens, the following can be used: estradiol, estriol, ethinylestradiol, their derivatives such as, for example, mono-esters and di-esters, such as estradiol-3,17&bgr;-diproprionate. </paragraph>
<paragraph id="P-0028" lvl="0"><number>&lsqb;0028&rsqb;</number> For the first time, a highly potent gestagen is made available, surprisingly enough, with (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione (hydroxytrienedione), and said gestagen has, in transdermal systems, especially matrix-transdermal systems based on polyacrylate adhesive, a surprisingly high solubility of up to about 20% by weight. Extraordinarily high transdermal flows can be achieved using such highly loaded systems. </paragraph>
<paragraph id="P-0029" lvl="0"><number>&lsqb;0029&rsqb;</number> The combination of high gestagenic potency, excellent matrix-loadability and skin penetration of the active ingredient makes it possible to make available efficient hormone replacement transdermal systems or birth control transdermal systems with use of hydroxytrienedione. </paragraph>
<paragraph id="P-0030" lvl="0"><number>&lsqb;0030&rsqb;</number> Of course, it is possible to include other adjuvants, such as the above-mentioned crystallization inhibitors and penetration intensifiers or solubilizers and/or solvents in the matrix-transdermal systems. Moreover, penetration enhancers can also be applied to increase the skin flows even before administration of the transdermal system to the corresponding skin parts. </paragraph>
<paragraph id="P-0031" lvl="0"><number>&lsqb;0031&rsqb;</number> The features of the invention that are disclosed in the description above as well as in the claims can be essential both individually and in any combination for the implementation of the invention in its various embodiments. </paragraph>
<paragraph id="P-0032" lvl="0"><number>&lsqb;0032&rsqb;</number> Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. </paragraph>
<paragraph id="P-0033" lvl="0"><number>&lsqb;0033&rsqb;</number> In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated. </paragraph>
<paragraph id="P-0034" lvl="0"><number>&lsqb;0034&rsqb;</number> The entire disclosure of all applications, patents and publications, cited above &lsqb;or below&rsqb;, and of corresponding European Patent application No. 00250449.6, filed Dec. 21, 2000 is hereby incorporated by reference. </paragraph>
</summary-of-invention>
<detailed-description>
<section>
<heading lvl="1">EXAMPLES </heading>
</section>
<section>
<heading lvl="1">Example 1 </heading>
</section>
<section>
<heading lvl="1">Production of Transdermal Systems with Hydroxytrienedione </heading>
<paragraph id="P-0035" lvl="0"><number>&lsqb;0035&rsqb;</number> Hydroxytrienedione is weighed in a beaker and with 25 g of a 30% solution of Kollidon<highlight><superscript>(R) </superscript></highlight>VA 64 in 2-propanol. 10 ml of 2-propanol is added. The mixture that is obtained is stirred for 5 minutes. The mixture is fed into the adhesive solution (Gelva 7881) that is introduced. The following table indicates the adhesive dry mass that is contained in the introduced volume of the adhesive solution. Then, it is stirred for another 0.5 hour. After polarization-microscopic checking to ensure the absence of crystals, the mixture that is obtained is coated by means of a 300 &mgr;m doctor blade on a liner that consists of fluoropolymer-coated polyester (Scotchpak<highlight><superscript>(R) </superscript></highlight>1022 Release Liner). It is dried for 20 minutes at 70&deg; C. and then laminated with a backing that consists of a co-laminate of PVC-PVDS with polyester (Saran-Hytrel<highlight><superscript>(R) </superscript></highlight>backing). Round patches with a surface area of 10 cm<highlight><superscript>2 </superscript></highlight>are punched from the three-layer laminate that is obtained and welded into a sealed bag that is made of aluminum compound foil.  
<table-cwu id="TABLE-US-00001">
<number>1</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="49PT" align="center"/>
<colspec colname="2" colwidth="56PT" align="center"/>
<colspec colname="3" colwidth="56PT" align="center"/>
<colspec colname="4" colwidth="56PT" align="center"/>
<thead>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry>Hydroxytriene-</entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry>Polyacrylate</entry>
<entry>dione</entry>
<entry>Kollidon<highlight><superscript>(R)</superscript></highlight></entry>
</row>
<row>
<entry></entry>
<entry>adhesive</entry>
<entry>Concentration</entry>
<entry>VA 64 Conc. in</entry>
</row>
<row>
<entry>Formulation</entry>
<entry>(Gelva<highlight><superscript>(R) </superscript></highlight>7881)</entry>
<entry>in TDS (m/m %)</entry>
<entry>TDS (m/m %)</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="49PT" align="center"/>
<colspec colname="2" colwidth="28PT" align="right"/>
<colspec colname="3" colwidth="28PT" align="left"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<colspec colname="5" colwidth="28PT" align="char" char="."/>
<colspec colname="6" colwidth="28PT" align="center"/>
<colspec colname="7" colwidth="28PT" align="center"/>
<tbody valign="top">
<row>
<entry>1</entry>
<entry>42</entry>
<entry>g</entry>
<entry>0.5 g</entry>
<entry>1</entry>
<entry>7.5 g</entry>
<entry>15</entry>
</row>
<row>
<entry>2</entry>
<entry>41</entry>
<entry>g</entry>
<entry>1.5 g</entry>
<entry>3</entry>
<entry>7.5 g</entry>
<entry>15</entry>
</row>
<row>
<entry>3</entry>
<entry>40</entry>
<entry>g</entry>
<entry>2.5 g</entry>
<entry>5</entry>
<entry>7.5 g</entry>
<entry>15</entry>
</row>
<row>
<entry>4</entry>
<entry>37.5</entry>
<entry>g</entry>
<entry>5.0 g</entry>
<entry>10</entry>
<entry>7.5 g</entry>
<entry>15</entry>
</row>
<row>
<entry>5</entry>
<entry>35</entry>
<entry>g</entry>
<entry>7.5 g</entry>
<entry>15</entry>
<entry>7.5 g</entry>
<entry>15</entry>
</row>
<row><entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0036" lvl="0"><number>&lsqb;0036&rsqb;</number> Gelva<highlight><superscript>(R) </superscript></highlight>7881 is a 50% polyacrylate adhesive solution in ethyl acetate (manufacturer: Solutia Company). In the above table, the dry weights are indicated as amounts weighed-in. </paragraph>
<paragraph id="P-0037" lvl="0"><number>&lsqb;0037&rsqb;</number> Scotchpak<highlight><superscript>(R) </superscript></highlight>1022 Release Liner is a product of the 3M Company, St. Paul, Minn., USA. Saran-Hytrel<highlight><superscript>(R) </superscript></highlight>backing is a product the Bertek Company, St. Albans, Vt., USA. </paragraph>
</section>
<section>
<heading lvl="1">Example 2 </heading>
</section>
<section>
<heading lvl="1">Penetration Studies </heading>
<paragraph id="P-0038" lvl="0"><number>&lsqb;0038&rsqb;</number> The results of the penetration studies with the corresponding five formulations with different contents of hydroxytrienedione are shown in the following tables. </paragraph>
<paragraph id="P-0039" lvl="0"><number>&lsqb;0039&rsqb;</number> The measurements were made with the following in-vitro-diffusion test. A tempered Franz-flow cell is divided into a donor compartment and an acceptor compartment by a 2 cm<highlight><superscript>2 </superscript></highlight>piece of excised skin from nude mice, whereby the horny layer faces toward the donor. A 3% or 5% solution of hydroxypropyl-&bgr;-cyclodextrin in buffer is pumped with the aid of a pneumatic pump from a tempered storage container through the acceptor compartment and collected with the aid of a fraction collector in glass vials that are exchanged at specific time intervals. </paragraph>
<paragraph id="P-0040" lvl="0"><number>&lsqb;0040&rsqb;</number> The active ingredient-containing patches are bonded to the donor side. </paragraph>
<paragraph id="P-0041" lvl="0"><number>&lsqb;0041&rsqb;</number> The content of active ingredients is determined in the individual fractions by means of HPLC/UV or GC/FID. </paragraph>
<paragraph id="P-0042" lvl="0"><number>&lsqb;0042&rsqb;</number> The transdermal in-vitro skin flow is indicated in ng/cm<highlight><superscript>2</superscript></highlight>/h:  
<table-cwu id="TABLE-US-00002">
<number>2</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Formulation 1: 1% Hydroxytrienedione</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="9">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="14PT" align="center"/>
<colspec colname="2" colwidth="28PT" align="center"/>
<colspec colname="3" colwidth="14PT" align="center"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<colspec colname="5" colwidth="21PT" align="center"/>
<colspec colname="6" colwidth="35PT" align="center"/>
<colspec colname="7" colwidth="14PT" align="center"/>
<colspec colname="8" colwidth="49PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>&lsqb;h&rsqb;</entry>
<entry>1</entry>
<entry>2</entry>
<entry>3</entry>
<entry>4</entry>
<entry>MW</entry>
<entry>SD</entry>
<entry>CV</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="9">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="14PT" align="char" char="."/>
<colspec colname="2" colwidth="28PT" align="char" char="."/>
<colspec colname="3" colwidth="14PT" align="char" char="."/>
<colspec colname="4" colwidth="28PT" align="char" char="."/>
<colspec colname="5" colwidth="21PT" align="char" char="."/>
<colspec colname="6" colwidth="35PT" align="char" char="."/>
<colspec colname="7" colwidth="14PT" align="char" char="."/>
<colspec colname="8" colwidth="49PT" align="char" char="."/>
<tbody valign="top">
<row>
<entry></entry>
<entry>1</entry>
<entry>2</entry>
<entry>1</entry>
<entry>0</entry>
<entry>0</entry>
<entry>1</entry>
<entry>1</entry>
<entry>86.6%</entry>
</row>
<row>
<entry></entry>
<entry>3</entry>
<entry>16</entry>
<entry>13</entry>
<entry>2</entry>
<entry>6</entry>
<entry>9</entry>
<entry>6</entry>
<entry>70.4%</entry>
</row>
<row>
<entry></entry>
<entry>5</entry>
<entry>55</entry>
<entry>36</entry>
<entry>11</entry>
<entry>27</entry>
<entry>32</entry>
<entry>18</entry>
<entry>57.2%</entry>
</row>
<row>
<entry></entry>
<entry>10</entry>
<entry>110</entry>
<entry>57</entry>
<entry>45</entry>
<entry>72</entry>
<entry>71</entry>
<entry>28</entry>
<entry>39.8%</entry>
</row>
<row>
<entry></entry>
<entry>18</entry>
<entry>79</entry>
<entry>59</entry>
<entry>51</entry>
<entry>76</entry>
<entry>66</entry>
<entry>13</entry>
<entry>20.2%</entry>
</row>
<row>
<entry></entry>
<entry>26</entry>
<entry>77</entry>
<entry>44</entry>
<entry>48</entry>
<entry>111</entry>
<entry>70</entry>
<entry>31</entry>
<entry>44.3%</entry>
</row>
<row>
<entry></entry>
<entry>34</entry>
<entry>56</entry>
<entry>32</entry>
<entry>47</entry>
<entry>52</entry>
<entry>47</entry>
<entry>11</entry>
<entry>22.6%</entry>
</row>
<row>
<entry></entry>
<entry>42</entry>
<entry>62</entry>
<entry>26</entry>
<entry>40</entry>
<entry>51</entry>
<entry>45</entry>
<entry>15</entry>
<entry>33.9%</entry>
</row>
<row>
<entry></entry>
<entry>50</entry>
<entry>40</entry>
<entry>20</entry>
<entry>39</entry>
<entry>42</entry>
<entry>35</entry>
<entry>10</entry>
<entry>29.0%</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0043" lvl="0"><number>&lsqb;0043&rsqb;</number>  
<table-cwu id="TABLE-US-00003">
<number>3</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Formulation 2: 3% Hydroxytrienedione</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="21PT" align="center"/>
<colspec colname="2" colwidth="28PT" align="center"/>
<colspec colname="3" colwidth="28PT" align="center"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<colspec colname="5" colwidth="28PT" align="center"/>
<colspec colname="6" colwidth="28PT" align="center"/>
<colspec colname="7" colwidth="28PT" align="center"/>
<colspec colname="8" colwidth="28PT" align="center"/>
<tbody valign="top">
<row>
<entry>&lsqb;h&rsqb;</entry>
<entry>1</entry>
<entry>2</entry>
<entry>3</entry>
<entry>4</entry>
<entry>MW</entry>
<entry>SD</entry>
<entry>CV</entry>
</row>
<row><entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="21PT" align="char" char="."/>
<colspec colname="2" colwidth="28PT" align="char" char="."/>
<colspec colname="3" colwidth="28PT" align="char" char="."/>
<colspec colname="4" colwidth="28PT" align="char" char="."/>
<colspec colname="5" colwidth="28PT" align="char" char="."/>
<colspec colname="6" colwidth="28PT" align="char" char="."/>
<colspec colname="7" colwidth="28PT" align="char" char="."/>
<colspec colname="8" colwidth="28PT" align="char" char="."/>
<tbody valign="top">
<row>
<entry>1</entry>
<entry>1</entry>
<entry>1</entry>
<entry>0</entry>
<entry>1</entry>
<entry>1</entry>
<entry>0</entry>
<entry>71.1%</entry>
</row>
<row>
<entry>3</entry>
<entry>20</entry>
<entry>24</entry>
<entry>4</entry>
<entry>16</entry>
<entry>16</entry>
<entry>9</entry>
<entry>54.3%</entry>
</row>
<row>
<entry>5</entry>
<entry>64</entry>
<entry>111</entry>
<entry>17</entry>
<entry>61</entry>
<entry>63</entry>
<entry>38</entry>
<entry>60.6%</entry>
</row>
<row>
<entry>10</entry>
<entry>118</entry>
<entry>171</entry>
<entry>109</entry>
<entry>207</entry>
<entry>151</entry>
<entry>46</entry>
<entry>30.6%</entry>
</row>
<row>
<entry>18</entry>
<entry>118</entry>
<entry>144</entry>
<entry>166</entry>
<entry>161</entry>
<entry>148</entry>
<entry>22</entry>
<entry>14.6%</entry>
</row>
<row>
<entry>26</entry>
<entry>106</entry>
<entry>147</entry>
<entry>197</entry>
<entry>158</entry>
<entry>152</entry>
<entry>37</entry>
<entry>24.5%</entry>
</row>
<row>
<entry>34</entry>
<entry>71</entry>
<entry>115</entry>
<entry>160</entry>
<entry>142</entry>
<entry>122</entry>
<entry>39</entry>
<entry>31.8%</entry>
</row>
<row>
<entry>42</entry>
<entry>54</entry>
<entry>114</entry>
<entry>120</entry>
<entry>116</entry>
<entry>101</entry>
<entry>31</entry>
<entry>30.9%</entry>
</row>
<row>
<entry>50</entry>
<entry>46</entry>
<entry>91</entry>
<entry>68</entry>
<entry>103</entry>
<entry>77</entry>
<entry>25</entry>
<entry>32.8%</entry>
</row>
<row><entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0044" lvl="0"><number>&lsqb;0044&rsqb;</number>  
<table-cwu id="TABLE-US-00004">
<number>4</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Formulation 3: 5% Hydroxytrienedione</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="21PT" align="center"/>
<colspec colname="2" colwidth="28PT" align="center"/>
<colspec colname="3" colwidth="28PT" align="center"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<colspec colname="5" colwidth="28PT" align="center"/>
<colspec colname="6" colwidth="28PT" align="center"/>
<colspec colname="7" colwidth="28PT" align="center"/>
<colspec colname="8" colwidth="28PT" align="center"/>
<tbody valign="top">
<row>
<entry>&lsqb;h&rsqb;</entry>
<entry>1</entry>
<entry>2</entry>
<entry>3</entry>
<entry>4</entry>
<entry>MW</entry>
<entry>SD</entry>
<entry>CV</entry>
</row>
<row><entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="21PT" align="char" char="."/>
<colspec colname="2" colwidth="28PT" align="char" char="."/>
<colspec colname="3" colwidth="28PT" align="char" char="."/>
<colspec colname="4" colwidth="28PT" align="char" char="."/>
<colspec colname="5" colwidth="28PT" align="char" char="."/>
<colspec colname="6" colwidth="28PT" align="char" char="."/>
<colspec colname="7" colwidth="28PT" align="char" char="."/>
<colspec colname="8" colwidth="28PT" align="char" char="."/>
<tbody valign="top">
<row>
<entry>1</entry>
<entry>2</entry>
<entry>1</entry>
<entry>2</entry>
<entry>2</entry>
<entry>1</entry>
<entry>1</entry>
<entry>67.3%</entry>
</row>
<row>
<entry>3</entry>
<entry>33</entry>
<entry>18</entry>
<entry>13</entry>
<entry>24</entry>
<entry>22</entry>
<entry>8</entry>
<entry>38.3%</entry>
</row>
<row>
<entry>5</entry>
<entry>104</entry>
<entry>57</entry>
<entry>48</entry>
<entry>86</entry>
<entry>74</entry>
<entry>26</entry>
<entry>34.9%</entry>
</row>
<row>
<entry>10</entry>
<entry>177</entry>
<entry>212</entry>
<entry>302</entry>
<entry>251</entry>
<entry>236</entry>
<entry>54</entry>
<entry>22.8%</entry>
</row>
<row>
<entry>18</entry>
<entry>168</entry>
<entry>280</entry>
<entry>228</entry>
<entry>345</entry>
<entry>255</entry>
<entry>75</entry>
<entry>29.4%</entry>
</row>
<row>
<entry>26</entry>
<entry>168</entry>
<entry>393</entry>
<entry>231</entry>
<entry>393</entry>
<entry>296</entry>
<entry>115</entry>
<entry>38.7%</entry>
</row>
<row>
<entry>34</entry>
<entry>196</entry>
<entry>206</entry>
<entry>240</entry>
<entry>263</entry>
<entry>226</entry>
<entry>31</entry>
<entry>13.7%</entry>
</row>
<row>
<entry>42</entry>
<entry>152</entry>
<entry>162</entry>
<entry>182</entry>
<entry>180</entry>
<entry>169</entry>
<entry>15</entry>
<entry>8.7%</entry>
</row>
<row>
<entry>50</entry>
<entry>147</entry>
<entry>147</entry>
<entry>221</entry>
<entry>138</entry>
<entry>163</entry>
<entry>39</entry>
<entry>23.9%</entry>
</row>
<row><entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0045" lvl="0"><number>&lsqb;0045&rsqb;</number>  
<table-cwu id="TABLE-US-00005">
<number>5</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Formulation 4: 10% Hydroxytrienedione</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="21PT" align="center"/>
<colspec colname="2" colwidth="28PT" align="center"/>
<colspec colname="3" colwidth="28PT" align="center"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<colspec colname="5" colwidth="28PT" align="center"/>
<colspec colname="6" colwidth="28PT" align="center"/>
<colspec colname="7" colwidth="28PT" align="center"/>
<colspec colname="8" colwidth="28PT" align="center"/>
<tbody valign="top">
<row>
<entry>&lsqb;h&rsqb;</entry>
<entry>1</entry>
<entry>2</entry>
<entry>3</entry>
<entry>4</entry>
<entry>MW</entry>
<entry>SD</entry>
<entry>CV</entry>
</row>
<row><entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="21PT" align="char" char="."/>
<colspec colname="2" colwidth="28PT" align="char" char="."/>
<colspec colname="3" colwidth="28PT" align="char" char="."/>
<colspec colname="4" colwidth="28PT" align="char" char="."/>
<colspec colname="5" colwidth="28PT" align="char" char="."/>
<colspec colname="6" colwidth="28PT" align="char" char="."/>
<colspec colname="7" colwidth="28PT" align="char" char="."/>
<colspec colname="8" colwidth="28PT" align="char" char="."/>
<tbody valign="top">
<row>
<entry>1</entry>
<entry>0</entry>
<entry>5</entry>
<entry>3</entry>
<entry>1</entry>
<entry>2</entry>
<entry>2</entry>
<entry>87.9%</entry>
</row>
<row>
<entry>3</entry>
<entry>16</entry>
<entry>74</entry>
<entry>60</entry>
<entry>35</entry>
<entry>46</entry>
<entry>26</entry>
<entry>55.6%</entry>
</row>
<row>
<entry>5</entry>
<entry>71</entry>
<entry>239</entry>
<entry>192</entry>
<entry>123</entry>
<entry>156</entry>
<entry>74</entry>
<entry>47.6%</entry>
</row>
<row>
<entry>10</entry>
<entry>349</entry>
<entry>466</entry>
<entry>428</entry>
<entry>477</entry>
<entry>430</entry>
<entry>58</entry>
<entry>13.5%</entry>
</row>
<row>
<entry>18</entry>
<entry>451</entry>
<entry>262</entry>
<entry>494</entry>
<entry>291</entry>
<entry>375</entry>
<entry>115</entry>
<entry>30.8%</entry>
</row>
<row>
<entry>26</entry>
<entry>695</entry>
<entry>269</entry>
<entry>463</entry>
<entry>242</entry>
<entry>417</entry>
<entry>209</entry>
<entry>50.2%</entry>
</row>
<row>
<entry>34</entry>
<entry>387</entry>
<entry>272</entry>
<entry>294</entry>
<entry>209</entry>
<entry>290</entry>
<entry>74</entry>
<entry>25.5%</entry>
</row>
<row>
<entry>42</entry>
<entry>257</entry>
<entry>232</entry>
<entry>242</entry>
<entry>165</entry>
<entry>224</entry>
<entry>41</entry>
<entry>18.2%</entry>
</row>
<row>
<entry>50</entry>
<entry>321</entry>
<entry>102</entry>
<entry>145</entry>
<entry>147</entry>
<entry>179</entry>
<entry>97</entry>
<entry>54.3%</entry>
</row>
<row><entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0046" lvl="0"><number>&lsqb;0046&rsqb;</number>  
<table-cwu id="TABLE-US-00006">
<number>6</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Formulation 5: 15% Hydroxytrienedione</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="35PT" align="center"/>
<colspec colname="2" colwidth="21PT" align="center"/>
<colspec colname="3" colwidth="35PT" align="center"/>
<colspec colname="4" colwidth="21PT" align="center"/>
<colspec colname="5" colwidth="35PT" align="center"/>
<colspec colname="6" colwidth="21PT" align="center"/>
<colspec colname="7" colwidth="49PT" align="center"/>
<tbody valign="top">
<row>
<entry>&lsqb;h&rsqb;</entry>
<entry>1</entry>
<entry>2</entry>
<entry>4</entry>
<entry>MW</entry>
<entry>SD</entry>
<entry>CV</entry>
</row>
<row><entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="35PT" align="char" char="."/>
<colspec colname="2" colwidth="21PT" align="char" char="."/>
<colspec colname="3" colwidth="35PT" align="char" char="."/>
<colspec colname="4" colwidth="21PT" align="char" char="."/>
<colspec colname="5" colwidth="35PT" align="char" char="."/>
<colspec colname="6" colwidth="21PT" align="char" char="."/>
<colspec colname="7" colwidth="49PT" align="char" char="."/>
<tbody valign="top">
<row>
<entry>2</entry>
<entry>2</entry>
<entry>5</entry>
<entry>5</entry>
<entry>4</entry>
<entry>2</entry>
<entry>49.7%</entry>
</row>
<row>
<entry>3</entry>
<entry>43</entry>
<entry>69</entry>
<entry>68</entry>
<entry>60</entry>
<entry>14</entry>
<entry>23.8%</entry>
</row>
<row>
<entry>5</entry>
<entry>213</entry>
<entry>182</entry>
<entry>187</entry>
<entry>194</entry>
<entry>17</entry>
<entry>8.6%</entry>
</row>
<row>
<entry>10</entry>
<entry>486</entry>
<entry>408</entry>
<entry>543</entry>
<entry>479</entry>
<entry>67</entry>
<entry>14.1%</entry>
</row>
<row>
<entry>18</entry>
<entry>374</entry>
<entry>404</entry>
<entry>276</entry>
<entry>352</entry>
<entry>67</entry>
<entry>19.0%</entry>
</row>
<row>
<entry>26</entry>
<entry>400</entry>
<entry>487</entry>
<entry>263</entry>
<entry>383</entry>
<entry>113</entry>
<entry>29.0%</entry>
</row>
<row>
<entry>34</entry>
<entry>386</entry>
<entry>218</entry>
<entry>220</entry>
<entry>275</entry>
<entry>96</entry>
<entry>35.1%</entry>
</row>
<row>
<entry>42</entry>
<entry>261</entry>
<entry>184</entry>
<entry>174</entry>
<entry>206</entry>
<entry>48</entry>
<entry>23.1%</entry>
</row>
<row>
<entry>50</entry>
<entry>271</entry>
<entry>176</entry>
<entry>160</entry>
<entry>202</entry>
<entry>60</entry>
<entry>29.6%</entry>
</row>
<row><entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0047" lvl="0"><number>&lsqb;0047&rsqb;</number> The mean values and standard deviations for the transdermal in-vitro-skin flows emerge from Table II below and are shown graphically in <cross-reference target="DRAWINGS">FIG. 2</cross-reference>.  
<table-cwu id="TABLE-US-00007">
<number>7</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">TABLE II</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Mean Values and Standard Deviations:</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="21PT" align="center"/>
<colspec colname="2" colwidth="35PT" align="center"/>
<colspec colname="3" colwidth="42PT" align="center"/>
<colspec colname="4" colwidth="42PT" align="center"/>
<colspec colname="5" colwidth="42PT" align="center"/>
<colspec colname="6" colwidth="35PT" align="center"/>
<tbody valign="top">
<row>
<entry>&lsqb;h&rsqb;</entry>
<entry>1%</entry>
<entry>3%</entry>
<entry>5%</entry>
<entry>10%</entry>
<entry>15%</entry>
</row>
<row><entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="21PT" align="char" char="."/>
<colspec colname="2" colwidth="35PT" align="center"/>
<colspec colname="3" colwidth="42PT" align="center"/>
<colspec colname="4" colwidth="42PT" align="center"/>
<colspec colname="5" colwidth="42PT" align="center"/>
<colspec colname="6" colwidth="35PT" align="center"/>
<tbody valign="top">
<row>
<entry>1</entry>
<entry>1 &plusmn; 1</entry>
<entry>1 &plusmn; 0</entry>
<entry>1 &plusmn; 1</entry>
<entry>2 &plusmn; 2</entry>
<entry>4 &plusmn; 2</entry>
</row>
<row>
<entry>3</entry>
<entry>9 &plusmn; 6</entry>
<entry>16 &plusmn; 9&ensp;</entry>
<entry>22 &plusmn; 8&ensp;</entry>
<entry>46 &plusmn; 26</entry>
<entry>60 &plusmn; 14</entry>
</row>
<row>
<entry>5</entry>
<entry>32 &plusmn; 18</entry>
<entry>63 &plusmn; 38</entry>
<entry>74 &plusmn; 26</entry>
<entry>156 &plusmn; 74&ensp;</entry>
<entry>194 &plusmn; 17&ensp;</entry>
</row>
<row>
<entry>10</entry>
<entry>71 &plusmn; 28</entry>
<entry>151 &plusmn; 46&ensp;</entry>
<entry>236 &plusmn; 54&ensp;</entry>
<entry>430 &plusmn; 58&ensp;</entry>
<entry>479 &plusmn; 67&ensp;</entry>
</row>
<row>
<entry>18</entry>
<entry>66 &plusmn; 13</entry>
<entry>148 &plusmn; 22&ensp;</entry>
<entry>255 &plusmn; 75&ensp;</entry>
<entry>375 &plusmn; 115</entry>
<entry>352 &plusmn; 67&ensp;</entry>
</row>
<row>
<entry>26</entry>
<entry>70 &plusmn; 31</entry>
<entry>152 &plusmn; 37&ensp;</entry>
<entry>296 &plusmn; 115</entry>
<entry>417 &plusmn; 209</entry>
<entry>383 &plusmn; 113</entry>
</row>
<row>
<entry>34</entry>
<entry>47 &plusmn; 11</entry>
<entry>122 &plusmn; 39&ensp;</entry>
<entry>226 &plusmn; 31&ensp;</entry>
<entry>290 &plusmn; 74&ensp;</entry>
<entry>275 &plusmn; 96&ensp;</entry>
</row>
<row>
<entry>42</entry>
<entry>45 &plusmn; 15</entry>
<entry>101 &plusmn; 31&ensp;</entry>
<entry>169 &plusmn; 15&ensp;</entry>
<entry>224 &plusmn; 41&ensp;</entry>
<entry>206 &plusmn; 48&ensp;</entry>
</row>
<row>
<entry>50</entry>
<entry>35 &plusmn; 10</entry>
<entry>77 &plusmn; 25</entry>
<entry>163 &plusmn; 39&ensp;</entry>
<entry>179 &plusmn; 97&ensp;</entry>
<entry>202 &plusmn; 60&ensp;</entry>
</row>
<row><entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">Example 3 </heading>
</section>
<section>
<heading lvl="1">Comparison Test Between Gestodene and Hydroxytrienedione </heading>
<paragraph id="P-0048" lvl="0"><number>&lsqb;0048&rsqb;</number> For comparison, the same measurements of the transdermal in-vitro skin flows&mdash;in otherwise identical formulation&mdash;were made with gestodene (GTD). The corresponding results emerge from the following tables. </paragraph>
<paragraph id="P-0049" lvl="7"><number>&lsqb;0049&rsqb;</number> Transdermal In-Vitro-Skin Flow in ng/cm<highlight><superscript>2</superscript></highlight>/h (1% by Weight-% of Gestodene)  
<table-cwu id="TABLE-US-00008">
<number>8</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="9">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="14PT" align="center"/>
<colspec colname="2" colwidth="35PT" align="center"/>
<colspec colname="3" colwidth="14PT" align="center"/>
<colspec colname="4" colwidth="35PT" align="center"/>
<colspec colname="5" colwidth="14PT" align="center"/>
<colspec colname="6" colwidth="35PT" align="center"/>
<colspec colname="7" colwidth="14PT" align="center"/>
<colspec colname="8" colwidth="42PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="8" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>&lsqb;h&rsqb;</entry>
<entry>1</entry>
<entry>2</entry>
<entry>3</entry>
<entry>4</entry>
<entry>MW</entry>
<entry>SD</entry>
<entry>CV</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="8" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="9">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="14PT" align="char" char="."/>
<colspec colname="2" colwidth="35PT" align="char" char="."/>
<colspec colname="3" colwidth="14PT" align="char" char="."/>
<colspec colname="4" colwidth="35PT" align="char" char="."/>
<colspec colname="5" colwidth="14PT" align="char" char="."/>
<colspec colname="6" colwidth="35PT" align="char" char="."/>
<colspec colname="7" colwidth="14PT" align="char" char="."/>
<colspec colname="8" colwidth="42PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>1</entry>
<entry>0</entry>
<entry>0</entry>
<entry>0</entry>
<entry>0</entry>
<entry>0</entry>
<entry>0</entry>
<entry>&mdash;</entry>
</row>
<row>
<entry></entry>
<entry>3</entry>
<entry>1</entry>
<entry>4</entry>
<entry>2</entry>
<entry>5</entry>
<entry>3</entry>
<entry>2</entry>
<entry>64.3%</entry>
</row>
<row>
<entry></entry>
<entry>5</entry>
<entry>5</entry>
<entry>31</entry>
<entry>14</entry>
<entry>18</entry>
<entry>17</entry>
<entry>11</entry>
<entry>64.3%</entry>
</row>
<row>
<entry></entry>
<entry>10</entry>
<entry>39</entry>
<entry>72</entry>
<entry>80</entry>
<entry>58</entry>
<entry>62</entry>
<entry>18</entry>
<entry>28.6%</entry>
</row>
<row>
<entry></entry>
<entry>18</entry>
<entry>77</entry>
<entry>46</entry>
<entry>110</entry>
<entry>36</entry>
<entry>67</entry>
<entry>34</entry>
<entry>49.8%</entry>
</row>
<row>
<entry></entry>
<entry>26</entry>
<entry>120</entry>
<entry>45</entry>
<entry>111</entry>
<entry>33</entry>
<entry>77</entry>
<entry>45</entry>
<entry>57.8%</entry>
</row>
<row>
<entry></entry>
<entry>34</entry>
<entry>50</entry>
<entry>39</entry>
<entry>83</entry>
<entry>31</entry>
<entry>51</entry>
<entry>23</entry>
<entry>44.6%</entry>
</row>
<row>
<entry></entry>
<entry>42</entry>
<entry>47</entry>
<entry>33</entry>
<entry>74</entry>
<entry>25</entry>
<entry>45</entry>
<entry>22</entry>
<entry>49.0%</entry>
</row>
<row>
<entry></entry>
<entry>50</entry>
<entry>37</entry>
<entry>27</entry>
<entry>44</entry>
<entry>22</entry>
<entry>32</entry>
<entry>10</entry>
<entry>30.0%</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0050" lvl="0"><number>&lsqb;0050&rsqb;</number> A matrix-TDS, in which the active ingredient is present in dissolved form, can be produced according to Example 1 with gestodene only up to about 1% (m/m). Moreover, it results in recrystallization phenomena of the gestodene. The skin flow cannot increase decisively. </paragraph>
<paragraph id="P-0051" lvl="0"><number>&lsqb;0051&rsqb;</number> The skin flows for 1%-matrix-TDS between hydroxytrienedione and gestodene are comparable, but allow the skin flows of hydroxytrienedione to increase significantly in that hydroxytrienedione in the matrix-TDS according to the invention is dissolved in a loadable manner up to about 20% (m/m). </paragraph>
<paragraph id="P-0052" lvl="0"><number>&lsqb;0052&rsqb;</number> The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples. </paragraph>
<paragraph id="P-0053" lvl="0"><number>&lsqb;0053&rsqb;</number> From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. </paragraph>
</section>
</detailed-description>
</subdoc-description>
<subdoc-claims>
<claim id="CLM-00001">
<claim-text><highlight><bold>1</bold></highlight>. Matrix-transdermal system that contains (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione, characterized in that the matrix comprises polyacrylate adhesive. </claim-text>
</claim>
<claim id="CLM-00002">
<claim-text><highlight><bold>2</bold></highlight>. Transdermal system according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, wherein the polyacrylate adhesive is a copolymer of at least two of the following monomers: 2-ethylhexylhexylacrylate, hydroxyethylhexylacrylate, vinyl acetate, vinyl pyrrolidone. </claim-text>
</claim>
<claim id="CLM-00003">
<claim-text><highlight><bold>3</bold></highlight>. Transdermal system according to <dependent-claim-reference depends_on="CLM-00002">claim 2</dependent-claim-reference>, wherein the polyacrylate adhesive is a copolymer that consists of 2-ethylhexylacrylate and hydroxyethylacrylate (Gelva<highlight><superscript>(R)</superscript></highlight>) or a copolymer of these monomers with vinyl acetate and 2-ethylhexylacrylate-N-vinyl-2-pyrrolidone (TSR<highlight><superscript>(R)</superscript></highlight>-adhesive of the Sekisui Company). </claim-text>
</claim>
<claim id="CLM-00004">
<claim-text><highlight><bold>4</bold></highlight>. Transdermal system according to one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00003">3</dependent-claim-reference>, characterized by a content of 0.1 to 20% by weight, preferably 1 to 15% of (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione in the matrix. </claim-text>
</claim>
<claim id="CLM-00005">
<claim-text><highlight><bold>5</bold></highlight>. Transdermal system according to one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00004">4</dependent-claim-reference>, wherein the matrix comprises at least one crystallization inhibitor. </claim-text>
</claim>
<claim id="CLM-00006">
<claim-text><highlight><bold>6</bold></highlight>. Transdermal system according to <dependent-claim-reference depends_on="CLM-00005">claim 5</dependent-claim-reference>, wherein the matrix comprises at least one N-vinyllactam polymer such as N-vinyl -1-aza-cycloheptan-2-one homopolymer, N-vinyl-piperidin-2-one homopolymer, polymers of vinylpyrrolidone such as polyvidone (Kollidon<highlight><superscript>(R)</superscript></highlight>) or co-polymers of vinylpyrrolidone with vinyl acetate (copovidones). </claim-text>
</claim>
<claim id="CLM-00007">
<claim-text><highlight><bold>7</bold></highlight>. Transdermal system according to one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00006">6</dependent-claim-reference>, characterized by an additional content of at least one of the following penetration intensifiers: 
<claim-text>Monovalent or multivalent alcohols such as ethanol, 1,2-propanediol or benzyl alcohol; saturated or unsaturated fatty alcohols with 8 to 18 carbon atoms, such as lauryl alcohol or cetyl alcohol; hydrocarbons such as mineral oil; saturated and unsaturated fatty acids with 8 to 18 carbon atoms such as stearic acid or oleic acid; fatty acid esters with up to 24 carbon atoms or dicarboxylic acid diesters with up to 24 carbon atoms, such as methyl ester, ethyl ester, isopropyl ester, butyl ester, sec-butyl ester, isobutyl ester, tert-butyl ester or monoglyceric acid ester of acetic acid, caproic acid, lauric acid, myristic acid, stearic acid and palmitic acid, phosphatide derivatives, such as lecithin, terpenes, urea and its derivatives or ethers, such as dimethyl isosorbide and diethylene glycol monoethyl ether. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00008">
<claim-text><highlight><bold>8</bold></highlight>. Transdermal system according to <dependent-claim-reference depends_on="CLM-00007">claim 7</dependent-claim-reference>, characterized by a content of at least one of the following penetration intensifiers: 
<claim-text>lauryl alcohol, 1,2-propanediol, methyl ester and especially the isopropyl ester of myristic acid or oleic acid, diisopropyl adipate and diisopropyl sebacate, lauric acid and oleic acid, as well as mixtures thereof. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00009">
<claim-text><highlight><bold>9</bold></highlight>. Transdermal system according to one of the preceding claims, characterized by an additional content of at least one estrogen such as estradiol, estriol, ethinylestradiol, derivatives thereof such as, for example, mono-esters and diesters such as estradiol-3,17&bgr;-diproprionate. </claim-text>
</claim>
<claim id="CLM-00010">
<claim-text><highlight><bold>10</bold></highlight>. Transdermal system according to one of the preceding claims, characterized by an additional content of at least one stabilizer, such as, for example, &bgr;-cyclodextrin.</claim-text>
</claim>
</subdoc-claims>
<subdoc-drawings id="DRAWINGS">
<heading lvl="0" align="CENTER">Drawings</heading>
<representative-figure>NONE</representative-figure>
<figure id="figure-D00001">
<image id="EMI-D00001" file="US20030003139A1-20030102-D00001.TIF" imf="TIFF" ti="DR"/>
</figure>
</subdoc-drawings>
</patent-application-publication>
